Skip to content
Precision for Medicine
Contact Us
false false
iStock-1476241215 (1) iStock-1476241215 (1)

Precision Drug Safety and Pharmacovigilance Services

Safeguarding patient health with proactive and rigorous monitoring and reporting
 At Precision for Medicine, we navigate the complexities of drug safety and pharmacovigilance with unparalleled expertise and advanced technology. Our commitment to excellence ensures regulatory compliance and patient safety across global clinical trials. As your trusted partner, we're dedicated to upholding the highest standards of care, making every decision with patient well-being and regulatory compliance in mind

Global capabilities in Drug Safety and Pharmacovigilance services

Precision for Medicine offers a spectrum of drug safety and pharmacovigilance services tailored to meet the diverse needs of our sponsors. Understanding that each clinical trial is unique, we have developed service models designed for flexibility and efficiency, ensuring that our sponsors can choose the level of support that best fits their project's scale and complexity.

Cancer cells_Protein expression

Customized solutions for every clinical phase

Whether you require comprehensive coverage for large-scale, multinational trials or targeted support for specialized studies, Precision provides. Our service models encompass everything from single case processing and periodic reporting to sophisticated analytics and full-spectrum pharmacovigilance programs.

Global Teams-Reach

A global team of experts

Our strength lies in our people. Precision's safety team—strategically distributed across the US, EU and APAC—brings together a wealth of knowledge and experience, averaging over 12 years in drug safety roles. This diverse team is not only proficient in a wide array of therapeutic areas but also deeply understands the nuances of regional and global regulatory requirements. Our integrated approach ensures consistent and reliable safety oversight, no matter where in the world your trials are conducted.

Drug safety excellence

Commitment to excellence

With a steadfast commitment to advancing patient safety and drug efficacy, Precision for Medicine stands as your dedicated partner. Our seasoned professionals, armed with extensive industry experience and an unparalleled understanding of pharmacovigilance, are ready to deliver excellence in safety services with the global reach and capability that today's complex clinical landscapes demand.

Leveraging Argus for compliance and end-to-end case management

We understand the imperative of navigating the intricate landscape of pharmacovigilance with unwavering compliance and security. Our utilization of Oracle's Argus Safety database is a testament to our commitment to providing sponsors with a seamless, secure, and comprehensive safety case management solution.

  • iStock-1499945987

    Unmatched Regulatory Adherence

    In an environment where regulatory demands are as dynamic as the clinical trials themselves, Precision offers peace of mind with Argus—the benchmark in meeting global compliance standards. From the moment an adverse event is captured to the detailed documentation required for regulatory submissions, our experts harness Argus's robust capabilities to ensure that every step aligns with the latest directives. Whether your trial spans one country or multiple continents, our vigilance in compliance safeguards your clinical journey.
  • iStock-1469171025

    Fortified Security and Confidentiality

    Your data’s integrity is paramount, which is why we anchor our drug safety operations in the secure and private infrastructure of Argus. Certified for protected health information, Argus delivers the confidentiality sponsors demand, without compromise. Our safety case management through Argus means your sensitive trial data is enveloped in a cloud of trust, meticulously managed to protect patient information and uphold the highest standards of data stewardship.
  • iStock-1419246395

    Comprehensive Case Management

    End-to-end case management with Argus empowers sponsors to oversee the safety profile of their products with crystal-clear clarity. From the initial intake of safety reports to the final step of data analysis and submission, Argus's intuitive platform streamlines the workflow. This integration ensures that critical safety information is captured, analyzed, and reported with precision, enabling informed decision-making and fostering proactive risk mitigation.

By integrating Argus's industry-leading platform into our pharmacovigilance services, Precision for Medicine elevates the standard for drug safety and pharmacovigilance. We offer sponsors a strategic partnership that delivers efficiency, compliance, and security—cornerstones of successful clinical trial management and the bedrock of patient safety.

Deep Expertise in Complex Diseases and Advanced Therapies

We recognize the patient journey throughout the development process. Our mission is to assist our partners in delivering innovative treatments to patients. Leverage our deep expertise in these therapeutic areas and modalities to advance your clinical goals.

Oncology Explore Rare diseases Explore Autoimmune Explore Gene Therapy Explore Cell Therapy Explore

Read the latest insights on Precision’s blog

Discover expert analysis and broaden your understanding through Precision’s Insights on current research, case studies, and trends. 

Explore our blog
Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Clinical Trials

Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat
Discover
Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

Clinical Trials

Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=187570680222, hs_child_table_id=0, hs_updated_at=1742413198455, hs_published_at=1748379090824, description=Christine has been ensuring high performance delivery of clinical research projects for more than 23 years. During this time, she has successfully led diverse teams across various cancer indications including renal, pancreatic, melanoma, lung, head and neck, breast, multiple myeloma, extra-nodal NK/T lymphoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Within the CRO setting she also supported the strategic development of over 50 hematology/oncology programs including complex Phase 1 projects in immuno-oncology and autologous cell therapy. She also led the establishment of a novel oncology research infrastructure which accelerated study activations for Phase 1 solid tumor studies. Christine obtained her master’s degree in public health at the University of Texas where she also trained in the development and implementation of clinical and epidemiologic research at the Coordinating Center for Clinical Trials as well as the Center for Occupational and Environment Health., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christine%20Lusk-1.png',altText='Christine Lusk-1',fileId=187579105870}, lastname=Lusk, hs_initial_published_at=1742410730688, hs_created_by_user_id=26433386, hs_created_at=1742410650472, hs_is_edited=false, hs_deleted_at=0, name=Christine, job=Director, Project Management, slug=christine-lusk, hs_updated_by_user_id=51739740}, second={hs_id=190691157084, hs_child_table_id=0, hs_updated_at=1748379058655, hs_published_at=1748379090824, description=Over the last 15 years, Megan has played a key role in advancing multiple oncology compounds through various stages of development, across numerous tumor types. Having worked at both biotech and CRO companies, Megan brings a comprehensive understanding of clinical operations and drug development. Megan maintains a focus on accelerating the development of innovative cancer therapies to improve patient outcomes worldwide., avatar=Image{width=3024,height=4032,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Megan%20Knoch.jpg',altText='Megan Knoch',fileId=190688034156}, lastname=Knoch, hs_initial_published_at=1748379090824, hs_created_by_user_id=26433386, hs_created_at=1748379018316, hs_is_edited=false, hs_deleted_at=0, name=Megan, slug=megan-knoch, hs_updated_by_user_id=26433386}, third={}})
  • Christine L. avatar

    Christine L.
  • Megan K. avatar

    Megan K.
Discover

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore